Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441344 in primary Sjögren's syndrome
NCT04572841Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of frexalimab in primary Sjögren's syndrome, sponsored by Sanofi. Started Nov 2020; status: completed.
02
Drugs
frexalimab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT04572841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572841.